Chemical Property of 1-deoxy-1-methylamino-D-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate
Chemical Property:
- Melting Point:195 - 198°C
- Purity/Quality:
-
98% *data from raw suppliers
Tafamidismeglumine >98% *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
Useful:
-
Description
In November 2011, the European Commission approved tafamidis
meglumine (Fx-1006A, PF-06291826) for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with stage 1
symptomatic polyneuropathy.
Tafamidis stabilizes both the wild type and mutant forms of TTR tetramer
and prevents tetramer dissociation by noncooperatively binding to the
two thyroxine binding sites. Tafamidis is the first approved medicine for
TTR-FAP. The Kd values for tafamidis for the two thyroxine binding sites
on TTR, as determined by isothermal titration calorimetry, were 3 nM and
278 nM, respectively. In another in vitro study using wild type TTR, V30M
mutant TTR, and V122I mutant TTR, it was shown that tafamidis inhibited
fibril formation in a concentration-dependent manner reaching EC50 at a
tafamidis:TTR stoichiometry of <1 (EC50 was in the range of 2.7–3.2 μM, corresponding to a tafamidis:TTR stoichiometry range of
0.75–0.9). Tafamidis has been synthesized by coupling 4-amino-3-
hydroxybenzoic acid with 3,5-dichlorobenzoyl chloride followed by dehydration using p-toluenesulfonic acid.
-
Uses
Tafamidis Meglumine is used as a potential therapeutics for COVID-19 and related viral infections
-
Clinical Use
Tafamidis meglumine is a transthyretin amyloid inhibitor that was approved for the treatment of
transthyretin amyloid polyneuropathy (ATTR-PN) and transthyretin familial amyloid polyneropathy
(TTR-FAP). These diseases represent a rare autosomal neurodegenerative disorder characterized
by autonomic, sensory and motor impairment which are typically fatal. Tafamidis was discovered at
The Scripps Research Institute and developed by Pfizer.
